WNK2 and Langerhans cell histiocytosis: Patients with LCH often have mutations in the mitogen-activated protein kinase (MAPK) cell signalling pathway6–12 and show signs of immune dysregulation5,13–15, although the nature of these defects and their significance to the etiology of LCH is not fully understood.